...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The British Journal of Surgery >Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers
【24h】

Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers

机译：接受新辅助化疗或放化疗的可切除食管和胃食管交界性癌症患者术后发病率和围手术期死亡率的荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The long-term survival benefits of neoadjuvant chemotherapy (NAC) and chemoradiotherapy (NACR) for oesophageal carcinoma are well established. Both are burdened, however, by toxicity that could contribute to perioperative morbidity and mortality. Methods MEDLINE, the Cochrane Library and Embase were searched to capture the incidence of any postoperative complications, cardiac complications, respiratory complications, anastomotic leakage, postoperative 30-day mortality, total postoperative mortality and treatment-related mortality in randomized clinical trials comparing NAC or NACR with surgery alone, or NAC versus NACR. Meta-analyses comparing NAC and NACR were conducted by using adjusted indirect comparison. Results Twenty-three relevant studies were identified. Comparing NAC or NACR with surgery alone, there was no increase in morbidity or mortality attributable to neoadjuvant therapy. Subgroup analysis of NACR for squamous cell carcinoma (SCC) suggested an increased risk of total postoperative mortality and treatment-related mortality compared with surgery alone: risk ratio 1·95 (95 per cent confidence interval 1·06 to 3·60; P = 0·032) and 1·97 (1·07 to 3·64; P = 0·030) respectively. A combination of direct comparison and adjusted indirect comparison showed no difference between NACR and NAC regarding morbidity or mortality. Conclusion Neither NAC nor NACR for oesophageal carcinoma increases the risk of postoperative morbidity or perioperative mortality compared with surgery alone. There was no clear difference between NAC and NACR. Care should be taken with NACR in oesophageal SCC, where an increased risk of postoperative mortality and treatment-related mortality was apparent.
机译：背景技术食管癌的新辅助化疗（NAC）和放化疗（NACR）的长期生存优势已得到公认。但是，两者都受到毒性的负担，而毒性可能会导致围手术期的发病率和死亡率增加。方法在NAC或NACR的随机临床试验中，对MEDLINE，Cochrane文库和Embase进行搜索，以了解任何术后并发症，心脏并发症，呼吸系统并发症，吻合口漏，术后30天死亡率，总术后死亡率和与治疗相关的死亡率。单独手术，或NAC与NACR对比。使用调整后的间接比较对NAC和NACR进行荟萃分析。结果鉴定了23项相关研究。将NAC或NACR与单纯手术相比，新辅助治疗的发病率或死亡率没有增加。 NACR鳞状细胞癌（SCC）的亚组分析表明，与单纯手术相比，总手术后死亡率和与治疗相关的死亡率风险增加：风险比1·95（95％置信区间1·06至3·60; P = 0·032）和1·97（1·07至3·64; P = 0·030）。直接比较和调整后的间接比较的组合显示，NACR和NAC在发病率或死亡率方面没有差异。结论与单独手术相比，NAC和NACR均不增加食管癌的术后发病或围手术期死亡的风险。 NAC和NACR之间没有明显的区别。食管鳞状细胞癌中应注意使用NACR，因为这明显增加了术后死亡率和与治疗有关的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号